Lipid prodrugs of rapamycin and its analogs and uses thereof
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
1. A compound of Formula 11:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 and R 44′ is independently H or D;
each of R a , R b , R c , R d , R e , R f , R g , and R h is independently selected from —CH 3 , —CH 2 D, -CHD 2 , and -CD 3 ; and
each of R 1 , R 14 , and R 35 is independently H, D, or a chemical entity of Formula 1:
or a pharmaceutically acceptable salt thereof, wherein:
A is the compound of Formula 11,
R 1′ and R 2′ are each independently hydrogen, an acid-labile group, a lipid, or —C(O)R 3′ ;
each R 3′ is independently a saturated or unsaturated, straight or branched, optionally substituted C 1-37 hydrocarbon chain;
X is —O—, —NR′—, —S—, —O(C 1-6 aliphatic)-O—, —O(C 1-6 aliphatic)-S—, —O(C 1-6 aliphatic)-NR′—, —S(C 1-6 aliphatic)-O—, —S(C 1-6 aliphatic)-S—, —S(C 1-6 aliphatic)-NR′—, —NR′(C 1-6 aliphatic)-O—, —NR′(C 1-6 aliphatic)-S—, or —NR′(C 1-6 aliphatic)-NR′—, wherein 0-2 methylene units of the C 1-6 aliphatic group are independently and optionally replaced with —O—, —NR′—, or —S— and the C 1-6 aliphatic group is independently and optionally substituted with 1, 2, or 3 deuterium or halogen atoms;
each R′ is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Y is absent or is —C(O)—, —C(NR′)—, or —C(S)—;
L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched, optionally substituted bivalent C 1-30 hydrocarbon chain, wherein 0-8 methylene units of L are independently replaced by -Cy-, —O—, —NR′—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —S(O)—, —S(O) 2 —, —C(S)—, —NR'S(O) 2 —, —S(O) 2 NR′—, —NR′C(O)—, —C(O)NR′—, —OC(O)NR′—, —NR′C(O)O—, or an amino acid; and wherein 1 methylene unit of L is optionally replaced with -M-; or
L is
wherein either the right-hand side or left-hand side of L is attached to A;
each -Cy- is independently an optionally substituted 3-6 membered bivalent saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each R 4′ and R 5′ is independently hydrogen, deuterium, halogen, —CN, —OR′, —NR′ 2 , —SR′, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a C 1-6 aliphatic group optionally substituted with —CN, —OR, —NR′ 2 , —SR′, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or the C 1-6 aliphatic is optionally substituted with 1, 2, 3, 4, 5, or 6 deuterium or halogen atoms; or
two instances of R 4′ or R 5′ attached to the same carbon atom, taken together with the carbon atom to which they are attached, form a 3-6 membered saturated monocyclic carbocyclic ring or 3-6 membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
-M- is a self-immolative group;
n is 0-18; and
each m is independently 0-6;
provided that at least one R 1 , R 14 , and R 35 is a chemical entity of Formula 1.
2. The compound of claim 1 , wherein R 1′ is —C(O)R 3′ .
3. The compound of claim 1 , wherein R 2′ is —C(O)R 3′ .
4. The compound of claim 1 , wherein, each R 3′ is independently a saturated or unsaturated, straight or branched C 2-37 hydrocarbon chain.
5. The compound of claim 1 , wherein X is —O—, —NH—, or —S—.
6. The compound of claim 1 , wherein L is a bivalent, saturated, straight, optionally substituted C 1-30 hydrocarbon chain, wherein 0-8 methylene units of L are independently replaced by -Cy-, —O—, —NR′—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —S(O)—, —S(O) 2 —, —NR'S(O) 2 —, —S(O) 2 NR′—, —NR′C(O)—, —C(O)NR′—, —OC(O)NR′—, —NR′C(O)O—, or an amino acid, and wherein 1 methylene unit of L is optionally replaced with -M-.
7. The compound of claim 6 , wherein L comprises
8. The compound of claim 1 , wherein L is
9. The compound of claim 8 , wherein -M- is
wherein R 6′ and R 7′ are each independently hydrogen or C 1-4 aliphatic.
10. The compound of claim 1 , wherein R 1 and R 14 are H or D and R 35 is a chemical entity of Formula 1.
11. The compound of claim 1 , wherein R 1 and R 35 are H or D and R 14 is a chemical entity of Formula 1.
12. The compound of claim 1 , wherein R 14 and R 35 are H or D and R 1 is a chemical entity of Formula 1.
13. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
14. A pharmaceutically acceptable composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
15. A method of treating an autoimmune disease, disorder, or condition in a patient in need thereof comprising administering to the patient the compound of 1.
16. The method of claim 15 , wherein the autoimmune disease, disorder, or condition is selected from Behçet's disease, pemphigus vulgaris, refractory incomplete systemic lupus crythematosus, immunoglobulin A nephropathy, small vessel vasculitis, or psoriasis.
17. A method of treating or preventing organ transplant rejection in a patient in need thereof, comprising administering to the patient the compound of claim 1 .
18. A method for treating a disease, disorder, or condition associated with hyperinflammation in a patient in need thereof, comprising administering to the patient the compound of claim 1 .